Clinical meaning
The menstrual cycle is a precisely coordinated neuroendocrine process governed by the hypothalamic-pituitary-ovarian (HPO) axis through pulsatile gonadotropin-releasing hormone (GnRH) secretion, pituitary gonadotropin release, and ovarian steroid feedback. The GnRH pulse generator in the arcuate nucleus of the hypothalamus must fire in a pulsatile pattern (every 60-90 minutes in the follicular phase, every 2-4 hours in the luteal phase) for normal gonadotropin secretion — continuous GnRH paradoxically downregulates pituitary GnRH receptors and suppresses FSH/LH (the pharmacologic basis of GnRH agonist therapy). The follicular phase begins with rising FSH stimulating a cohort of antral follicles; FSH induces aromatase expression in granulosa cells, converting thecal androgens to estradiol. By day 5-7, the dominant follicle emerges through its greater FSH receptor density and local autocrine/paracrine factors (activin, inhibin B, IGF-1), while non-dominant follicles undergo atresia as declining FSH falls below their survival threshold. Rising estradiol from the dominant follicle initially exerts negative feedback on pituitary FSH and LH; however, when estradiol exceeds approximately 200 pg/mL for 36-48 hours, feedback switches from negative to positive, triggering the mid-cycle LH surge that initiates ovulation approximately 36 hours later through proteolytic follicular wall breakdown and oocyte release. Post-ovulation, the ruptured follicle undergoes luteinization to form the corpus luteum, which secretes progesterone and estradiol. Progesterone converts the proliferative endometrium to the secretory phase (glandular coiling, glycogen accumulation, stromal decidualization) required for embryo implantation. If fertilization does not occur, the corpus luteum involutes by day 26-28, progesterone and estradiol levels plummet, triggering prostaglandin-mediated endometrial arteriolar vasoconstriction, tissue ischemia, metalloproteinase-driven stromal breakdown, and menstrual shedding. The luteal phase is consistently approximately 14 days regardless of cycle length — cycle variability reflects follicular phase duration. The clinician applies this physiology to interpret cycle-timed laboratory assessments (FSH/LH day 2-4, progesterone day 21), diagnose anovulation (hypogonadotropic versus hypergonadotropic hypogonadism), evaluate the progesterone withdrawal test, and manage menstrual disorders from hypothalamic, pituitary, ovarian, and uterine etiologies.